Tirabrutinib Hydrochloride
Tirabrutinib hydrochloride is the hydrochloride salt form of tirabrutinib, a selective irreversible BTK inhibitor with activity in CNS lymphoma and other B-cell malignancies. See tirabrutinib for complete pharmacological details. This salt formulation is used in approved oral preparations for lymphoma treatment.
Masse moléculaire
490,9000 g/mol
TPSA
105,00 Ų
Aires thérapeutiques
Mécanisme d'action
Irreversibly inhibits Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway that drives the survival and proliferation of malignant B cells.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Irreversibly inhibits Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway that drives the survival and proliferation of malignant B cells.
Structure 2D
Cite this structure
Embed this structure
SMILES
CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1.Cl
InChI
InChI=1S/C25H22N6O3.ClH/c1-2-6-21(32)29-14-13-18(15-29)31-24-22(23(26)27-16-28-24)30(25(31)33)17-9-11-20(12-10-17)34-19-7-4-3-5-8-19;/h3-5,7-12,16,18H,13-15H2,1H3,(H2,26,27,28);1H/t18-;/m1./s1
Molecular Formula
C25H23ClN6O3
HBD / HBA
2 / 6
Liaisons Rotatives
4
Atomes Lourds
35
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
Tirabrutinib hydrochloride is the hydrochloride salt form of tirabrutinib, a selective irreversible BTK inhibitor with activity in CNS lymphoma and other B-cell malignancies. See tirabrutinib for complete pharmacological details. This salt formulation is used in approved oral preparations for lymphoma treatment.
Irreversibly inhibits Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway that drives the survival and proliferation of malignant B cells.
Yes, Tirabrutinib Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5314600. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 71571562. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tirabrutinib-hydrochloride"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tirabrutinib-hydrochloride/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tirabrutinib-hydrochloride/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tirabrutinib-hydrochloride/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tirabrutinib-hydrochloride"></drugfyi-drug>